Stock Track | Zoetis Plummets 8.16% in Pre-Market as 2025 Outlook Disappoints

Stock Track

13 Feb

Zoetis-1.07%Pre-market

Zoetis Inc. (ZTS), the leading animal healthcare company, experienced a sharp decline of 8.16% in its stock price during the pre-market trading session on Thursday. The plummet was primarily driven by the company's underwhelming guidance for the year 2025, which fell short of Wall Street's expectations.

In its fourth-quarter earnings report, Zoetis forecasted its adjusted earnings per share (EPS) for 2025 to be in the range of $6.00 to $6.10, missing analysts' average estimate of $6.29. Additionally, the company projected its full-year revenue for 2025 to be between $9.23 billion and $9.38 billion, lower than the consensus estimate of $9.57 billion.

The disappointing outlook was attributed to several factors, including the impact of a stronger U.S. dollar and the divestiture of certain product portfolios, such as the medicated feed additive product line and certain water-soluble products, which were sold to Phibro Animal Health for $350 million. These divestitures had a slightly larger impact than initially anticipated, according to J.P. Morgan analyst Chris Schott.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

no data

No relevant data is available

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1189338057"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189338057\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1189338057?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189338057","market":"hk","top_or_hot":-1,"title":"Stock Track | Zoetis Plummets 8.16% in Pre-Market as 2025 Outlook Disappoints","media":"Stock Track","content":"<p>Zoetis Inc. (ZTS), the leading animal healthcare company, experienced a sharp decline of 8.16% in its stock price during the pre-market trading session on Thursday. The plummet was primarily driven by the company's underwhelming guidance for the year 2025, which fell short of Wall Street's expectations.</p>\n\n<p>In its fourth-quarter earnings report, Zoetis forecasted its adjusted earnings per share (EPS) for 2025 to be in the range of $6.00 to $6.10, missing analysts' average estimate of $6.29. Additionally, the company projected its full-year revenue for 2025 to be between $9.23 billion and $9.38 billion, lower than the consensus estimate of $9.57 billion.</p>\n\n<p>The disappointing outlook was attributed to several factors, including the impact of a stronger U.S. dollar and the divestiture of certain product portfolios, such as the medicated feed additive product line and certain water-soluble products, which were sold to Phibro Animal Health for $350 million. These divestitures had a slightly larger impact than initially anticipated, according to J.P. Morgan analyst Chris Schott.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Zoetis Plummets 8.16% in Pre-Market as 2025 Outlook Disappoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Zoetis Plummets 8.16% in Pre-Market as 2025 Outlook Disappoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-13 22:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zoetis Inc. (ZTS), the leading animal healthcare company, experienced a sharp decline of 8.16% in its stock price during the pre-market trading session on Thursday. The plummet was primarily driven by the company's underwhelming guidance for the year 2025, which fell short of Wall Street's expectations.</p>\n\n<p>In its fourth-quarter earnings report, Zoetis forecasted its adjusted earnings per share (EPS) for 2025 to be in the range of $6.00 to $6.10, missing analysts' average estimate of $6.29. Additionally, the company projected its full-year revenue for 2025 to be between $9.23 billion and $9.38 billion, lower than the consensus estimate of $9.57 billion.</p>\n\n<p>The disappointing outlook was attributed to several factors, including the impact of a stronger U.S. dollar and the divestiture of certain product portfolios, such as the medicated feed additive product line and certain water-soluble products, which were sold to Phibro Animal Health for $350 million. These divestitures had a slightly larger impact than initially anticipated, according to J.P. Morgan analyst Chris Schott.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZTS","symbol_name":"Zoetis Inc.","start_time":0,"source_url":"","article_id":"1189338057","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189338057","pubTimestamp":1739458237,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Zoetis Inc. , the leading animal healthcare company, experienced a sharp decline of 8.16% in its stock price during the pre-market trading session on Thursday. The plummet was primarily driven by the company's underwhelming guidance for the year 2025, which fell short of Wall Street's expectations.In its fourth-quarter earnings report, Zoetis forecasted its adjusted earnings per share  for 2025 to be in the range of $6.00 to $6.10, missing analysts' average estimate of $6.29. Additionally, the c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZTS":"Zoetis Inc."},"translate_title":"2025年前景令人失望，硕腾股价盘前暴跌8.16%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZTS":1},"content_text":"Zoetis Inc. (ZTS), the leading animal healthcare company, experienced a sharp decline of 8.16% in its stock price during the pre-market trading session on Thursday. The plummet was primarily driven by the company's underwhelming guidance for the year 2025, which fell short of Wall Street's expectations.\nIn its fourth-quarter earnings report, Zoetis forecasted its adjusted earnings per share (EPS) for 2025 to be in the range of $6.00 to $6.10, missing analysts' average estimate of $6.29. Additionally, the company projected its full-year revenue for 2025 to be between $9.23 billion and $9.38 billion, lower than the consensus estimate of $9.57 billion.\nThe disappointing outlook was attributed to several factors, including the impact of a stronger U.S. dollar and the divestiture of certain product portfolios, such as the medicated feed additive product line and certain water-soluble products, which were sold to Phibro Animal Health for $350 million. These divestitures had a slightly larger impact than initially anticipated, according to J.P. Morgan analyst Chris Schott.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."

Consult now
Download APP
Scan QR code to download the app.